바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

1오늘 방문

739누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

AntibodystaleThe First Hospital of Jilin Uni…Phase 2

Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab (Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleDaping Hospital and the Researc…Phase 2

TP + Cetuximab + Tislelizumab (TP + Cetuximab + Tislelizumab)

LA HNSCC · LA HNSCC

#LAHNSCC#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleBlokhin's Russian Cancer Resear…Phase 2

mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy (mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy)

Neoplasms · Neoplasms

#Neoplasms#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleEli LillyPhase 2

cetuximab + docetaxel + cisplatin (cetuximab + docetaxel + cisplatin)

Esophageal Cancer · Esophageal Cancer

#EsophagealCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleEli LillyPreclinical

Cetuximab Dabrafenib Tislelizumab (Cetuximab Dabrafenib Tislelizumab)

Advanced Colorectal Cancer · Advanced Colorectal Cancer

#AdvancedColorectalCancer#Antibody#Preclinical#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleEli LillyPhase 3

Cetuximab + Platinum (Cetuximab + Platinum, Cisplatin or Carboplatin, Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU))

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleFudan UniversityPhase 3

mFOLFOX6 + Cetuximab (mFOLFOX6 + Cetuximab)

Colorectal Cancer; Liver Metastases · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#항체#면역항체+3

임상시험 1상태 RECRUITING

AntibodystaleHanmi Pharmaceutical Company Li…Phase 1

HM95573, cetuximab (HM95573, cetuximab)

Locally Advanced Solid Tumor; Metastatic Solid Tumor · Locally Advanced Solid Tumor

#LocallyAdvancedSolidTumor#Antibody#Phase1#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleEli LillyPhase 2

cetuximab+immunochemotharpy (cetuximab+immunochemotharpy)

Head and Neck Squamous Carcinoma · Head and Neck Squamous Carcinoma

#HeadandNeckSquamousCarcinoma#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleGroupe Oncologie Radiotherapie …Phase 2

Carbo, 5FU, Cetuximab (Carbo, 5FU, Cetuximab)

Metastatic or Recurrent Head and Neck Squamous Cell Cancer · Metastatic or Recurrent Head and Neck Sq

#MetastaticorRecurrentHeadandNeck#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleShahid Beheshti University of M…Phase 3

injection of bevacizumab and erythropoietin (injection of bevacizumab and erythropoietin)

Refractory Diabetic Macular Edema · FRα

#FR#Antibody#Phase3#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleShahid Beheshti University of M…Phase 3

injection of bevacizumab (injection of bevacizumab)

Refractory Diabetic Macular Edema · FRα

#FR#Antibody#Phase3#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleInnoventPhase 2

Sintilimab and Bevacizumab Combined with Radiotherapy (Sintilimab and Bevacizumab Combined with Radiotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleSecond Affiliated Hospital of G…Phase 2

TACE combined with sorafenib and tislelizumab (TACE combined with sorafenib and tislelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleM.D. Anderson Cancer CenterPhase 2

Standard Dose Bevacizumab (Standard Dose Bevacizumab)

Brain Cancer; Glioblastoma · Brain Cancer

#BrainCancer#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleM.D. Anderson Cancer CenterPhase 2

Low Dose Bevacizumab (Low Dose Bevacizumab)

Brain Cancer; Glioblastoma · Brain Cancer

#BrainCancer#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleFudan UniversityPhase 2

Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin (Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin)

Mesothelioma · Mesothelioma

#Mesothelioma#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleXinqiao Hospital of ChongqingPhase 2

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

NSCLC Stage IV Without EGFR/ALK Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 RECRUITING

AntibodystaleM.D. Anderson Cancer CenterPhase 1

LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide)

Metastatic Esophageal; Gastric Cancer · Metastatic Esophageal

#MetastaticEsophageal#Antibody#Phase1#항체#면역항체+3

임상시험 1상태 RECRUITING

AntibodystaleRochePhase 1

Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid (Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid)

Sarcoma; Soft Tissue Sarcoma · Sarcoma

#Sarcoma#Antibody#Phase1#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleM.D. Anderson Cancer CenterPhase 1

LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide)

Metastatic Esophageal; Gastric Cancer · Metastatic Esophageal

#MetastaticEsophageal#Antibody#Phase1#항체#면역항체+3

임상시험 1상태 RECRUITING

AntibodystaleRochePhase 1

and approved biosimilars (Bevacizumab, Bevacizumab (and approved biosimilars))

Solid Tumor; Colorectal Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#항체#면역항체+3

임상시험 1상태 DISCONTINUED

AntibodystaleTranslational Oncology Research…Phase 2

Erlotinib + Bevacizumab (Erlotinib + Bevacizumab)

Prostate Cancer · Prostate Cancer

#ProstateCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleChinese PLA General HospitalPhase 2

CAPOX combined with bevacizumab and Tislelizumab (CAPOX combined with bevacizumab and Tislelizumab)

Advanced Gastroesophageal Adenocarcinoma; First-line Therapy · Advanced Gastroesophageal Adenocarcinoma

#AdvancedGastroesophagealAdenocar#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleSe-Hoon LeePhase 2

Olaparib+Bevacizumab to SCLC patients (Olaparib+Bevacizumab to SCLC patients)

Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

99 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 1 / 739

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab (Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab)

TP + Cetuximab + Tislelizumab (TP + Cetuximab + Tislelizumab)

mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy (mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy)

cetuximab + docetaxel + cisplatin (cetuximab + docetaxel + cisplatin)

Cetuximab Dabrafenib Tislelizumab (Cetuximab Dabrafenib Tislelizumab)

Cetuximab + Platinum (Cetuximab + Platinum, Cisplatin or Carboplatin, Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU))

mFOLFOX6 + Cetuximab (mFOLFOX6 + Cetuximab)

HM95573, cetuximab (HM95573, cetuximab)

cetuximab+immunochemotharpy (cetuximab+immunochemotharpy)

Carbo, 5FU, Cetuximab (Carbo, 5FU, Cetuximab)

injection of bevacizumab and erythropoietin (injection of bevacizumab and erythropoietin)

injection of bevacizumab (injection of bevacizumab)

Sintilimab and Bevacizumab Combined with Radiotherapy (Sintilimab and Bevacizumab Combined with Radiotherapy)

TACE combined with sorafenib and tislelizumab (TACE combined with sorafenib and tislelizumab)

Standard Dose Bevacizumab (Standard Dose Bevacizumab)

Low Dose Bevacizumab (Low Dose Bevacizumab)

Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin (Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin)

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide)

Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid (Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid)

LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide)

and approved biosimilars (Bevacizumab, Bevacizumab (and approved biosimilars))

Erlotinib + Bevacizumab (Erlotinib + Bevacizumab)

CAPOX combined with bevacizumab and Tislelizumab (CAPOX combined with bevacizumab and Tislelizumab)

Olaparib+Bevacizumab to SCLC patients (Olaparib+Bevacizumab to SCLC patients)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab (Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab)

TP + Cetuximab + Tislelizumab (TP + Cetuximab + Tislelizumab)

mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy (mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy)

cetuximab + docetaxel + cisplatin (cetuximab + docetaxel + cisplatin)

Cetuximab Dabrafenib Tislelizumab (Cetuximab Dabrafenib Tislelizumab)

Cetuximab + Platinum (Cetuximab + Platinum, Cisplatin or Carboplatin, Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU))

mFOLFOX6 + Cetuximab (mFOLFOX6 + Cetuximab)

HM95573, cetuximab (HM95573, cetuximab)

cetuximab+immunochemotharpy (cetuximab+immunochemotharpy)

Carbo, 5FU, Cetuximab (Carbo, 5FU, Cetuximab)

injection of bevacizumab and erythropoietin (injection of bevacizumab and erythropoietin)

injection of bevacizumab (injection of bevacizumab)

Sintilimab and Bevacizumab Combined with Radiotherapy (Sintilimab and Bevacizumab Combined with Radiotherapy)

TACE combined with sorafenib and tislelizumab (TACE combined with sorafenib and tislelizumab)

Standard Dose Bevacizumab (Standard Dose Bevacizumab)

Low Dose Bevacizumab (Low Dose Bevacizumab)

Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin (Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin)

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide)

Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid (Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid)

LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide)

and approved biosimilars (Bevacizumab, Bevacizumab (and approved biosimilars))

Erlotinib + Bevacizumab (Erlotinib + Bevacizumab)

CAPOX combined with bevacizumab and Tislelizumab (CAPOX combined with bevacizumab and Tislelizumab)

Olaparib+Bevacizumab to SCLC patients (Olaparib+Bevacizumab to SCLC patients)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab (Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab)

TP + Cetuximab + Tislelizumab (TP + Cetuximab + Tislelizumab)

mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy (mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy)

cetuximab + docetaxel + cisplatin (cetuximab + docetaxel + cisplatin)

Cetuximab Dabrafenib Tislelizumab (Cetuximab Dabrafenib Tislelizumab)

Cetuximab + Platinum (Cetuximab + Platinum, Cisplatin or Carboplatin, Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU))

mFOLFOX6 + Cetuximab (mFOLFOX6 + Cetuximab)

HM95573, cetuximab (HM95573, cetuximab)

cetuximab+immunochemotharpy (cetuximab+immunochemotharpy)

Carbo, 5FU, Cetuximab (Carbo, 5FU, Cetuximab)

injection of bevacizumab and erythropoietin (injection of bevacizumab and erythropoietin)

injection of bevacizumab (injection of bevacizumab)

Sintilimab and Bevacizumab Combined with Radiotherapy (Sintilimab and Bevacizumab Combined with Radiotherapy)

TACE combined with sorafenib and tislelizumab (TACE combined with sorafenib and tislelizumab)

Standard Dose Bevacizumab (Standard Dose Bevacizumab)

Low Dose Bevacizumab (Low Dose Bevacizumab)